FDA/NCI DRUGS FOR CANCER PREVENTION "WHITE PAPER"
Executive Summary
FDA/NCI DRUGS FOR CANCER PREVENTION "WHITE PAPER" should be completed by the end of the summer, FDA's Division of Oncology and Pulmonary Drugs forecasts. The white paper will focus on drugs for cancer prevention and will cover all phases of drug development. The guideline will detail procedures for studies in animals, toxicology and efficacy, as well as examine the design and endpoints for Phase I, Phase II and Phase III cancer prevention clinical trials.